Company
-
Sprout Social Jumps on M&A Chatter — What the Adobe Rumors Really Mean!
Sprout Social drew attention after takeover rumors linked Adobe to a possible bid. Strong 13% revenue growth, record margins, and…
Read More » -
Voyager Technologies Just Bought Estes—Here’s Why It Could Redefine Missile Defense!
Voyager’s acquisition of Estes Energetics boosts vertical integration in missile tech, aligning with DoD priorities and strengthening supply-chain control, but…
Read More » -
Kaltura Goes All-In on Avatars & AI — Will eSelf Make or Break Them?
Kaltura is making waves after agreeing to buy eSelf.ai for $27M, a move that accelerates its shift from video SaaS…
Read More » -
Alphabet’s Race Toward a $4 Trillion Valuation Signals a New Phase of AI Dominance
Alphabet is approaching a $4 trillion market value after a recent surge that reshaped investor expectations for the future of…
Read More » -
Pacira BioSciences Pops As Activist Investor Calls For Sale — What You Need To Know!
Pacira jumped into M&A chatter after investor DOMA Perpetual urged a full sale, arguing the biotech could fetch $66/share. Activist…
Read More » -
Braskem Shares Soar: Could This Be the Comeback Moment for the Debt-Laden Giant?
Braskem jumped after a $230M settlement eased major legal risk and reports of IG4 Capital seeking control sparked hopes for…
Read More » -
Exodus Just Bought Grateful—Here’s How It Could Disrupt Stablecoin Payments
Exodus’ acquisition of Grateful adds stablecoin payments, merchant tools, and global expansion potential, helping the company move toward a broader…
Read More » -
Avadel Stock Soars As Lundbeck Outbids Alkermes—Will A Bidding War Break Out?
Lundbeck’s higher $23 bid lifts Avadel’s near-term upside and sparks talk of a bidding war, but its non-binding terms, CVR…
Read More » -
TreeHouse Foods Just Scored A Major Deal—But Is It Worth $2.9 Billion?
Investindustrial’s bid sent TreeHouse Foods soaring as the PE firm targets its margin-expansion plan, private-label growth, strong cash flow, and…
Read More » -
Intellia Therapeutics Loses A Patient & $BILLIONS In Value — Can It Recover?
Intellia plunged after a patient died in its ATTR trial, prompting FDA holds on two Phase III studies and raising…
Read More »
